Literature DB >> 1346399

Epidermal growth factor and transforming growth factor-alpha decrease gamma interferon receptors and induction of intercellular adhesion molecule (ICAM-1) on cultured keratinocytes.

R S Mitra1, B J Nickoloff.   

Abstract

The link between the epidermal keratinocytes of the skin and the activated T lymphocytes of the immune system is mediated by a variety of cytokines, including gamma interferon (IFN-gamma). We studied the influence of keratinocyte mitogens such as transforming growth factor-alpha (TGF-alpha), epidermal growth factor (EGF), and somatomedin-C (SM-C) on the ligand binding of 32P-labeled IFN-gamma to cultured keratinocytes derived from normal appearing adult human skin. Keratinocytes placed in a medium devoid of mitogens become growth arrested, and these quiescent cells expressed 2.4 times (28,900 versus 12,200 sites/cell) as many high affinity IFN-gamma receptors (Kd = 0.22 nM) compared to keratinocytes which were actively growing in medium containing TGF-alpha (25 ng/ml) or EGF (10 ng/ml). The reduction in IFN-gamma receptor sites by TGF-alpha/EGF was mitogen specific, as adding SM-C (500 ng/ml) did not have any effect on ligand binding, although it similarly stimulated keratinocyte growth. The reduction in IFN-gamma receptors was time dependent, occurring primarily after 24-48 hours of change in tissue culture conditions. The reduction in the number of high affinity IFN-gamma receptors by TGF-alpha/EGF had immunobiological consequences, because quiescent keratinocytes in basal medium had an increased expression of HLA-DR and intercellular adhesion molecule-1 (ICAM-1) induced by IFN-gamma, compared to actively growing TGF-alpha/EGF treated keratinocytes. These results suggest that rapidly proliferating keratinocytes exposed to TGF-alpha/EGF but not SM-C are capable of altering their response to IFN-gamma by decreasing their number of cell surface high affinity receptors for IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1346399     DOI: 10.1002/jcp.1041500207

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  7 in total

1.  EGFR inhibitors, MHC expression and immune responses : Can EGFR inhibitors be used as immune response modifiers?

Authors:  Brian P Pollack
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

2.  STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients.

Authors:  Raghvendra M Srivastava; Sumita Trivedi; Fernando Concha-Benavente; Jie Hyun-Bae; Lin Wang; Raja R Seethala; Barton F Branstetter; Soldano Ferrone; Robert L Ferris
Journal:  Cancer Immunol Res       Date:  2015-05-13       Impact factor: 11.151

Review 3.  Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.

Authors:  Anna E Kersh; Spencer Ng; Yun Min Chang; Maiko Sasaki; Susan N Thomas; Haydn T Kissick; Gregory B Lesinski; Ragini R Kudchadkar; Edmund K Waller; Brian P Pollack
Journal:  J Clin Pharmacol       Date:  2017-11-14       Impact factor: 3.126

4.  Cytokines, neuropeptides, and other factors in cutaneous immune responses.

Authors:  J W Bauer; S W Caughman
Journal:  West J Med       Date:  1994-02

5.  Inhibition of MHC-I by Brucella abortus is an early event during infection and involves EGFR pathway.

Authors:  Lis N Velásquez; M Ayelén Milillo; M Victoria Delpino; Aldana Trotta; M Florencia Mercogliano; Roberto G Pozner; Roxana Schillaci; Patricia V Elizalde; Guillermo H Giambartolomei; Paula Barrionuevo
Journal:  Immunol Cell Biol       Date:  2016-11-29       Impact factor: 5.126

6.  Increased epidermal cell proliferation in normal human skin in vivo following local administration of interferon-gamma.

Authors:  J N Barker; J R Goodlad; E L Ross; C C Yu; R W Groves; D M MacDonald
Journal:  Am J Pathol       Date:  1993-04       Impact factor: 4.307

Review 7.  Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.

Authors:  Anna E Kersh; Maiko Sasaki; Lee A Cooper; Haydn T Kissick; Brian P Pollack
Journal:  Front Pharmacol       Date:  2016-09-26       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.